The 2019 MM&M/Deloitte Healthcare Marketers Trend Report
Following a midterm election that changed the composition of Congress, pharma finds itself in the crosshairs on the pricing front. Did industry anticipate the changing atmosphere when setting last year’s marketing budgets (or, for that matter, those of 2019)? Has the sugar high from the 2017 tax bill worn off? To what extent have consultancies made inroads on agencies as they compete for marketing dollars? How big a role does marketing automation play?
These and other questions will be answered in MM&M’s proprietary survey of director-level-and-up biopharma and device marketing execs. As in years past, it will showcase a wealth of exclusive research and offer insight into marketers’ current thinking via new data on budgets (and their growth/decline), channel usage, and challenges/opportunities (such as the intensified influence of payers). Charts and tables bring the survey data to life.
At this year’s CES Health, a host of immersive technology – everything from platforms that purport to track users’ brain patterns to tagging devices designed to monitor orthopedic implants – made its debut. We showcase the most promising new developments, explaining how they could ultimately redefine patient marketing as it is practiced today.
SXSW 2019 preview
The last few years have seen SXSW’s health track surge in influence. We check in with festival organizers and presenters to see what they have in store for the 2019 iteration.
Despite their preeminence in the world of pharma wholesaling, McKesson, Cardinal Health, and AmerisourceBergen remain somewhat of a mystery to many constituencies within the industry. In this exclusive report, the three largest drug distributors demystify their operations and talk about how they’ve evolved, both as individual entities and as a critical sub-industry.
2018 Pro ad report
This report offers a look-back at the biopharma industry’s complete 2018 medical journal ad spend, provided by third-party data firm Kantar Media. We reveal the top-spending drugmakers, pharma brands, and therapeutic categories, as well as the journals that reaped the most ad pages.